Comdisco sells Medical Exchange assets
Asset management and equipment refurbishing firm Comdisco has sold certain assets of its medical equipment refurbishing and mobile diagnostic business, Comdisco Medical Exchange, to a private investment group. The group includes former Comdisco
Asset management and equipment refurbishing firm Comdisco has sold certain assets of its medical equipment refurbishing and mobile diagnostic business, Comdisco Medical Exchange, to a private investment group. The group includes former Comdisco Healthcare Group president Chip Halverson and other Comdisco Healthcare executives in addition to New York City-based healthcare investment company Galen Partners.
Comdisco made the move as part of its strategy of focusing on newer generations of diagnostic imaging equipment that require lighter refurbishment, according to the Rosemont, IL-based firm. The company is also expanding the scope of its technology offerings to include continuity, availability, network, and desktop management services.
The new business will operate under the name MedAssets Exchange, and will serve as an independent preferred supplier of reconditioned and interim diagnostic equipment to industry organizations, including Comdisco. Comdiscos divested assets comprise their used medical equipment inventory, including angiography, cardiac catheterization, C-arm, CT, digital imaging, MRI, x-ray, and mobile diagnostic and imaging systems. MedAssets Exchange will be based in Wood Dale, IL, and will utilize the facility that served as Comdisco Medical Exchanges refurbishing center.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
